1
|
Rubio EM, Hilton JF, Bent S, Parvataneni R, Oberman E, Saberi NS, Varon S, Schembri M, Waetjen LE, Jacoby VL. Complementary and Alternative Medicine Use Among Women with Symptomatic Uterine Fibroids. J Womens Health (Larchmt) 2023; 32:546-552. [PMID: 37023398 DOI: 10.1089/jwh.2022.0094] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 04/08/2023] Open
Abstract
Objective: The aim of this study is to examine complementary and alternative medicine (CAM) use among women with symptomatic uterine fibroids in the United States. Materials and Methods: In this cross-sectional analysis of baseline data from a multicenter, prospective cohort study of premenopausal women undergoing surgery for symptomatic fibroids and who enrolled in the Uterine Leiomyoma Treatment with Radiofrequency Ablation study from 2017 to 2019, we contrast women indicating use of at least one CAM modality specifically for fibroid symptoms against women using CAM for other reasons and CAM nonusers. Multivariable logistic regression models were performed to identify participant characteristics independently associated with CAM use for fibroids. Results: Among 204 women, 55% were Black/African American and the mean age was 42 (standard deviation 6.6) years. CAM use was common (67%), with 42% (95% confidence interval [CI]: 35%-49%) reporting use of CAM specifically to treat fibroid symptoms. Most commonly, CAM treatments used for fibroids were diet (62%) and herbs (52%), while CAM treatments for other reasons were exercise (80%) and massage (43%). On average, each participant who reported CAM use utilized three different types of CAM modalities. In a multivariable model, participants were more likely to use CAM for fibroids if they had pelvic pressure (odds ratio [OR] 2.50, 95% CI: 1.07-5.87, p = 0.04), a body-mass index lower than average (OR 0.76, 95% CI: 0.60-0.97, p = 0.03), and a lower health-related quality of life score (OR 0.61, 95% CI: 0.46-0.81, p = 0.001). Conclusions: In this diverse sample of women with symptomatic fibroids, CAM use was highly prevalent. Our findings highlight the need for providers to query patients about CAM use and understand the role of CAM in fibroid management. ClinicalTrials.gov Identifier: NCT02100904.
Collapse
Affiliation(s)
- Elia Marina Rubio
- Department of Epidemiology and Biostatistics, University of California, San Francisco, California, USA
| | - Joan F Hilton
- Department of Epidemiology and Biostatistics, University of California, San Francisco, California, USA
| | - Stephen Bent
- Department of Epidemiology and Biostatistics, University of California, San Francisco, California, USA
| | - Ram Parvataneni
- Department of Obstetrics and Gynecology, University of California, Los Angeles, Los Angeles, California, USA
- University of California Fibroid Network, USA
| | - Erica Oberman
- Department of Obstetrics and Gynecology, University of California, Los Angeles, Los Angeles, California, USA
- University of California Fibroid Network, USA
| | - Naghmeh Salamat Saberi
- University of California Fibroid Network, USA
- Department of Obstetrics and Gynecology, University of California, Irvine, Irvine, California, USA
| | - Shira Varon
- University of California Fibroid Network, USA
- Department of Obstetrics and Gynecology, University of California, San Diego, San Diego, California, USA
| | - Michael Schembri
- Department of Obstetrics, Gynecology and Reproductive Sciences, University of California, San Francisco, California, USA
| | - L Elaine Waetjen
- University of California Fibroid Network, USA
- Department of Obstetrics and Gynecology, University of California, Davis, Davis, California, USA
| | - Vanessa L Jacoby
- Department of Epidemiology and Biostatistics, University of California, San Francisco, California, USA
- University of California Fibroid Network, USA
- Department of Obstetrics, Gynecology and Reproductive Sciences, University of California, San Francisco, California, USA
| |
Collapse
|
2
|
Meek AG, Park TL, Oberman E, Wielopolski L. A prospective study of prostate specific antigen levels in patients receiving radiotherapy for localized carcinoma of the prostate. Int J Radiat Oncol Biol Phys 1990; 19:733-41. [PMID: 1698754 DOI: 10.1016/0360-3016(90)90504-d] [Citation(s) in RCA: 39] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/28/2022]
Abstract
Prostate Specific Antigen (PSA) is becoming the preferred tumor marker in the management of prostate cancer. Prostate Specific Antigen levels fall exponentially after radical prostatectomy with a half-life of between 2 and 3 days. Persistently elevated Prostate Specific Antigen levels beyond 7 half-lives suggest occult residual disease and may serve as an indication for post operative adjunctive therapy. The change in Prostate Specific Antigen levels during a course of radical external beam radiotherapy for prostate cancer has not been described. In this study of 81 patients receiving radiotherapy for primary prostate cancer, 47 had elevated Prostate Specific Antigen levels prior to therapy and 35 had serial measurement of Prostate Specific Antigen during their course of treatment. Working on an assumption that in patients with radioresponsive localized prostate cancer Prostate Specific Antigen levels will fall exponentially during the radiotherapy, a half-life of 43 +/- 11 days was derived. Prostate Specific Antigen half-life appears independent of stage, grade, or pretreatment Prostate Specific Antigen level and may be an independent prognostic indicator. A prolonged Prostate Specific Antigen half-life may suggest untreated or resistant disease and serve as an indication for adjuvant hormonal treatment in patients receiving radiotherapy for primary prostate cancer.
Collapse
Affiliation(s)
- A G Meek
- Department of Radiation Oncology, State University of New York, Stony Brook 11794
| | | | | | | |
Collapse
|